Om Nalamasu Senior VP & CTO, Applied Materials

Om Nalamasu Senior VP & CTO, Applied Materials

Dr. Omkaram (Om) Nalamasu is senior vice president and chief technology officer (CTO) for Applied Materials. He brings extensive experience and passion to the role of CTO, where he is leading the development of new product pipelines, securing government funding for key strategic projects and building a world-class team to maintain Applied Materials’ technology leadership in the industries it serves and enable growth into new markets. Dr. Nalamasu is also the president of Applied Ventures, LLC, the venture capital fund of Applied Materials, overseeing the financial and strategic investments in early and growth-stage privately held companies.

A world-renowned expert in materials science and technology and one of our industry’s respected forward thinkers, Dr. Nalamasu has championed a renewed focus on the company’s innovation culture through various internal development programs and open innovation methods. He has strengthened Applied Materials’ strategic relationships with universities and research institutes around the world including IIT Bombay.

Dr. Nalamasu joined Applied Materials in 2006, after serving as vice president of research at Rensselaer Polytechnic Institute (RPI). He has held key research and development leadership positions at AT&T Bell Laboratories, Bell Laboratories/Lucent Technologies, and Agere Systems, Inc., and was director of Bell Laboratories’ Nanofabrication Research Laboratory, MEMS and Waveguides Research, and Condensed Matter Physics organizations.

His research interests include nanomanufacturing, nanopatterning, electronic and photonic materials, and lithography, with special emphasis on applying patterning and materials know-how for device fabrication for electronics, photonics and energy applications.

Dr. Nalamasu has made seminal contributions to the fields of optical lithography and polymeric materials science and technology. He has received numerous awards, authored more than 180 papers, review articles and books, and holds more than 35 patents.

Dr. Nalamasu is a member of the board of directors of Semiconductor Research Corporation and The Tech Museum, and serves on the National Academies Panel on Materials Science and Engineering. He sits on several technical advisory boards and university advisory committees, and received his Ph.D. from the University of British Columbia, Vancouver, Canada.

The Fourth Annual Rosenman Symposium

At the Rosenman Institute we’re here to support medtech startups. We connect entrepreneurs to the resources and expertise they need to commercialize their technologies. Helping innovators forge connections is why we’ve brought our legendary symposium back for a fourth year. Join us in San Francisco on June 21 to learn from leaders in the field, meet CEOs of exciting early-stage companies, and get insight on how industry forms strategic partnerships with startups.

Rosenman Innovators

During the symposium, we’ll hear lightning presentations from 10 entrepreneurs: the Rosenman Innovators. The Rosenman Innovators are the entrepreneurs selected as finalists for the Medtech Track of the QB3 Life Science Pitch Summits. Rosenman Innovators are eligible to be chosen to receive a wide range of valuable medtech services (valued at $250k) including lab time, prototyping, and design support, plus cash prizes.

Medical Devices Reimagined

Every day, engineers integrate new technology into medical devices. But with the pace of advances in technology and discovery, the potential for devices now far outstrips the state of the art. It is essential for us to reimagine the possibilities. Where better to reimagine devices than the Rosenman Symposium, held at UCSF Mission Bay? Together, we can speed the development of exciting technologies to improve the lives of patients.

How Precision Medicine is Transforming Medical Devices

Precision medicine is transforming the field of medical devices. How can engineers, investors, clinicians, and medical device professionals anticipate the future? Our June symposium brings Bay Area stakeholders together to share insights and discuss how entrepreneurs can bring new technologies to market for the benefit of patients.

Empowering the Next Generation of Medical Innovators

The route for taking a medical device from idea to product generally isn’t smooth. Surgeons know what problems they need solved, but they often know little about bioengineering. Engineers are great at building products, but often don’t know whether a device is needed or wanted in the clinic.

That’s why we created the Rosenman Institute, a UCSF-based initiative devoted to medical device innovation. The Institute, named for the late Dan Rosenman, a biomedical engineer, is a collaboration between QB3, the UCSF Department of Surgery, the UCSF Department of Bioengineering and Therapeutic Sciences, and medical device professionals. Our goal is to connect physician innovators with engineering expertise and business support to accelerate medical device innovation.

This symposium will inspire clinicians and engineers to innovate; introduce the resources available at the Rosenman Institute; and enable entrepreneurs to share their stories and their perspectives on the future of medical device innovation. It will also provide an opportunity for networking with entrepreneurs, physicians, investors, biomedical engineers, scientists, mentors and representatives of major device